Clinical Scorecard: Pediatric Clinical Progression Scale: An Emerging Tool for Assessing Severity and Advancement of Respiratory Syncytial Virus in Children
At a Glance
Category
Detail
Condition
Respiratory syncytial virus (RSV) infection in infants and young children
Key Mechanisms
Ordinal severity scoring (CPS-Ped) measuring clinical progression and respiratory support levels
Target Population
Infants hospitalized with RSV-related critical illness, primarily under 8 months of age
Care Setting
Pediatric intensive care units (PICUs) and hospital settings
Key Highlights
RSV causes significant morbidity with 33 million acute lower respiratory infections and 3.6 million hospitalizations annually worldwide.
CPS-Ped score ranges from 0 (discharged at baseline) to 8 (death) and assesses clinical improvement over hospitalization days.
CPS-Ped requires fewer participants in clinical trials to detect treatment effects compared to traditional outcomes like length of stay.
Guideline-Based Recommendations
Diagnosis
Use CPS-Ped score to assess severity and clinical progression in infants hospitalized with RSV.
Apply PALICC-2 guidelines for stratifying severe respiratory outcomes within the CPS-Ped framework.
Management
Consider nirsevimab monoclonal antibody for RSV prevention in infants under 8 months during RSV season and certain high-risk infants in their second season.
Maternal vaccination with Abrysvo between 32 and 36 weeks gestation is recommended to protect infants during their first RSV season.
Recognize the need for RSV antivirals for infected children, especially those not eligible for prophylaxis.
Monitoring & Follow-up
Calculate CPS-Ped scores at admission and serially on days 2–7, 10, and 14 to monitor clinical improvement.
Define clinical improvement as CPS-Ped score ≤2 or a decrease of ≥3 points from admission score.
Risks
Infants <3 months, premature infants (especially <29 weeks gestation), those with underlying respiratory conditions, and those requiring invasive mechanical ventilation within 24 hours have higher risk of poor clinical improvement.
Patient & Prescribing Data
Infants under 8 months of age during their first RSV season and certain high-risk infants in their second season
Nirsevimab and maternal Abrysvo vaccination are safe and efficacious but limited by cost and accessibility, leaving many infants unprotected.
Clinical Best Practices
Utilize CPS-Ped as a standardized, clinically meaningful outcome metric in pediatric RSV clinical trials to improve detection of treatment effects.
Incorporate multiple levels of respiratory support in severity scoring to reflect current clinical practices, including high-flow nasal cannula use.
Leverage electronic health record integration for automated CPS-Ped scoring to facilitate large-scale studies.
Be aware of practice variability in respiratory support modalities when interpreting CPS-Ped scores.
A small observational study in collegiate football players found microbiome associations after nonconcussive head impacts, though findings were limited by severe underpowering and high attrition
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
